Jones Financial Companies
ENSC icon

Jones Financial Companies’s Ensysce Biosciences ENSC Stock Holding History

Jones Financial Companies’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41
Closed -$38 – 4786
2025
Q4 		$38 Buy
+41
New +$76 ﹤0.01% 4351

Other funds holding ENSC

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jones Financial Companies's ENSC Position: Q1 2026 in Review

Jones Financial Companies sold out of Ensysce Biosciences (ENSC) in Q1 2026, closing a stake of 41 shares — an estimated $38 sold.

Jones Financial Companies first reported a position in ENSC in Q4 2025 and held it in 1 quarter. The position peaked at $38 in Q4 2025. 15 funds tracked by Wall St. Rank hold ENSC as of Q1 2026.

  • Jones Financial Companies reported no remaining Ensysce Biosciences position as of Q1 2026 after selling out during the quarter.
  • Jones Financial Companies sold 41 Ensysce Biosciences shares in Q1 2026, an estimated $38.
  • Jones Financial Companies first reported a position in Ensysce Biosciences in Q4 2025 and held it in 1 quarter.
  • Jones Financial Companies's Ensysce Biosciences position peaked at $38 in Q4 2025.
  • 15 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.